{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:13:46Z","timestamp":1792818826812,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-025-10535-w","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:47:30Z","timestamp":1749898050000},"page":"1141-1153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Unveiling the complexity of nonobstructive hypertrophic cardiomyopathy"],"prefix":"10.1007","volume":"30","author":[{"given":"Leopoldo","family":"Ordine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Polizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Canciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Moscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Martorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Angela","family":"Losi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,14]]},"reference":[{"issue":"4","key":"10535_CR1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA et al (2022) Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 79(4):372\u2013389","journal-title":"J Am Coll Cardiol"},{"key":"10535_CR2","doi-asserted-by":"publisher","unstructured":"Aimo A, Todiere G, Barison A, Tomasoni D, Panichella G, Masri A et al (2025) Diagnosis and management of hypertrophic cardiomyopathy: European vs. American guidelines. Heart Fail Rev 30(2):315\u2013325. https:\/\/doi.org\/10.1007\/s10741-024-10464-0","DOI":"10.1007\/s10741-024-10464-0"},{"key":"10535_CR3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.CIR.26.2.161","volume":"26","author":"E Braunwald","year":"1962","unstructured":"Braunwald E, Brockenbrough EC, Morrow AG (1962) Hypertrophic subaortic stenosis--a broadened concept. Circulation 26:161\u2013165","journal-title":"Circulation"},{"issue":"37","key":"10535_CR4","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626","journal-title":"Eur Heart J"},{"key":"10535_CR5","doi-asserted-by":"publisher","unstructured":"Ommen SR, Ho CY, Asif IM et al (2024) 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2024 Aug 20;150(8):e198. https:\/\/doi.org\/10.1161\/CIR.0000000000001277.]. Circulation. 2024;149(23):e1239\u2013e1311. https:\/\/doi.org\/10.1161\/CIR.0000000000001250","DOI":"10.1161\/CIR.0000000000001277"},{"issue":"21","key":"10535_CR6","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","volume":"114","author":"MS Maron","year":"2006","unstructured":"Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT et al (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114(21):2232\u20132239","journal-title":"Circulation"},{"key":"10535_CR7","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ijcard.2023.04.005","volume":"382","author":"D Massera","year":"2023","unstructured":"Massera D, Sherrid MV, Maron MS, Rowin EJ, Maron BJ (2023) How common is hypertrophic cardiomyopathy\u2026 really?: Disease prevalence revisited 27 years after CARDIA. Int J Cardiol 382:64\u201367","journal-title":"Int J Cardiol"},{"issue":"9","key":"10535_CR8","doi-asserted-by":"crossref","first-page":"e007230","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230","volume":"13","author":"M Canepa","year":"2020","unstructured":"Canepa M, Fumagalli C, Tini G, Vincent-Tompkins J, Day SM, Ashley EA et al (2020) Temporal trend of age at diagnosis in hypertrophic cardiomyopathy: an analysis of the international Sarcomeric Human Cardiomyopathy Registry. Circ Heart Fail 13(9):e007230","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10535_CR9","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/hrt.2007.126003","volume":"94","author":"JS Shah","year":"2008","unstructured":"Shah JS, Esteban MTT, Thaman R, Sharma R, Mist B, Pantazis A et al (2008) Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 94(10):1288\u20131294","journal-title":"Heart"},{"issue":"7","key":"10535_CR10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian AJ, Braunwald E (2017) Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749\u2013770","journal-title":"Circ Res"},{"issue":"2","key":"10535_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/cardiogenetics13020009","volume":"13","author":"F Borrelli","year":"2023","unstructured":"Borrelli F, Losi MA, Canciello G, Todde G, Perillo EF, Ordine L et al (2023) Sarcomeric versus non-sarcomeric HCM. Cardiogenetics 13(2):92\u2013105","journal-title":"Cardiogenetics"},{"issue":"3","key":"10535_CR12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41588-025-02087-4","volume":"57","author":"R Tadros","year":"2025","unstructured":"Tadros R, Zheng SL, Grace C, Jord\u00e0 P, Francis C, West DM et al (2025) Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. Nat Genet 57(3):530\u2013538","journal-title":"Nat Genet"},{"issue":"6","key":"10535_CR13","doi-asserted-by":"crossref","first-page":"e004200","DOI":"10.1161\/CIRCGEN.123.004200","volume":"16","author":"L Curran","year":"2023","unstructured":"Curran L, de Marvao A, Inglese P, McGurk KA, Schiratti PR, Clement A et al (2023) Genotype-phenotype taxonomy of hypertrophic cardiomyopathy. Circulation Genomic Precision Med 16(6):e004200","journal-title":"Circulation Genomic Precision Med"},{"issue":"19","key":"10535_CR14","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","volume":"74","author":"S Neubauer","year":"2019","unstructured":"Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF et al (2019) Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol 74(19):2333\u20132345","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10535_CR15","doi-asserted-by":"crossref","first-page":"e038208","DOI":"10.1161\/JAHA.124.038208","volume":"14","author":"K Sugiura","year":"2025","unstructured":"Sugiura K, Kubo T, Inoue S, Nomura S, Yamada T, Tobita T et al (2025) Unveiling clinical and genetic distinctions in pure-apical versus distal-dominant apical hypertrophic cardiomyopathy. J Am Heart Assoc 14(6):e038208","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10535_CR16","doi-asserted-by":"crossref","first-page":"e011435","DOI":"10.1161\/CIRCHEARTFAILURE.123.011435","volume":"17","author":"JM Federspiel","year":"2024","unstructured":"Federspiel JM, Reil JC, Xu A, Scholtz S, Batzner A, Maack C et al (2024) Retrofitting the heart: explaining the enigmatic septal thickening in hypertrophic cardiomyopathy. Circ Heart Fail 17(5):e011435","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10535_CR17","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.CIR.79.3.580","volume":"79","author":"HM Lever","year":"1989","unstructured":"Lever HM, Karam RF, Currie PJ, Healy BP (1989) Hypertrophic cardiomyopathy in the elderly. Distinctions from the young based on cardiac shape. Circulation 79(3):580\u2013589","journal-title":"Circulation"},{"issue":"3","key":"10535_CR18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jcmg.2008.02.008","volume":"1","author":"IS Syed","year":"2008","unstructured":"Syed IS, Ommen SR, Breen JF, Tajik AJ (2008) Hypertrophic cardiomyopathy: identification of morphological subtypes by echocardiography and cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 1(3):377\u2013379","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"10535_CR19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4065\/81.4.459","volume":"81","author":"J Binder","year":"2006","unstructured":"Binder J, Ommen SR, Gersh BJ, Van Driest SL, Tajik AJ, Nishimura RA et al (2006) Echocardiography-guided genetic testing in hypertrophic cardiomyopathy: septal morphological features predict the presence of myofilament mutations. Mayo Clin Proc 81(4):459\u2013467","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10535_CR20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/ehjci\/jeac233","volume":"24","author":"U Hermida","year":"2023","unstructured":"Hermida U, Stojanovski D, Raman B, Ariga R, Young AA, Carapella V et al (2023) Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: beyond basal septal hypertrophy. Eur Heart J Cardiovasc Imaging 24(6):807\u2013818","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"8","key":"10535_CR21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.acvd.2013.05.002","volume":"106","author":"R Martin","year":"2013","unstructured":"Martin R, Lairez O, Boudou N, M\u00e9jean S, Lhermusier T, Dumonteil N et al (2013) Relation between left ventricular outflow tract obstruction and left ventricular shape in patients with hypertrophic cardiomyopathy: a cardiac magnetic resonance imaging study. Arch Cardiovasc Dis 106(8):440\u2013447","journal-title":"Arch Cardiovasc Dis"},{"issue":"5","key":"10535_CR22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jchf.2017.09.011","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron BJ, Rowin EJ, Udelson JE, Maron MS (2018) Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. JACC Heart Fail 6(5):353\u2013363","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10535_CR23","doi-asserted-by":"crossref","first-page":"e003689","DOI":"10.1161\/CIRCHEARTFAILURE.116.003689","volume":"10","author":"M Covella","year":"2017","unstructured":"Covella M, Rowin EJ, Hill NS, Preston IR, Milan A, Opotowsky AR et al (2017) Mechanism of progressive heart failure and significance of pulmonary hypertension in obstructive hypertrophic cardiomyopathy. Circ Heart Fail 10(4):e003689","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10535_CR24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1161\/01.CIR.103.11.1492","volume":"103","author":"W Mazur","year":"2001","unstructured":"Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R et al (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103(11):1492\u20131496","journal-title":"Circulation"},{"issue":"3","key":"10535_CR25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/01.CIR.99.3.344","volume":"99","author":"SF Nagueh","year":"1999","unstructured":"Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Zoghbi WA, Qui\u00f1ones MA et al (1999) Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 99(3):344\u2013347","journal-title":"Circulation"},{"issue":"10","key":"10535_CR26","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","volume":"128","author":"AJ Marian","year":"2021","unstructured":"Marian AJ (2021) Molecular genetic basis of hypertrophic cardiomyopathy. Circ Res 128(10):1533\u20131553","journal-title":"Circ Res"},{"issue":"11","key":"10535_CR27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrcardio.2016.140","volume":"13","author":"S Sen-Chowdhry","year":"2016","unstructured":"Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ (2016) Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol 13(11):651\u2013675","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"10535_CR28","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","volume":"349","author":"F Cecchi","year":"2003","unstructured":"Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349(11):1027\u20131035","journal-title":"N Engl J Med"},{"issue":"1","key":"10535_CR29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0735-1097(87)80159-6","volume":"10","author":"RO Cannon","year":"1987","unstructured":"Cannon RO, Schenke WH, Maron BJ, Tracy CM, Leon MB, Brush JE et al (1987) Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 10(1):53\u201362","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10535_CR30","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jacc.2016.07.751","volume":"68","author":"CE Raphael","year":"2016","unstructured":"Raphael CE, Cooper R, Parker KH, Collinson J, Vassiliou V, Pennell DJ et al (2016) Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 68(15):1651\u20131660","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10535_CR31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(86)80181-4","volume":"8","author":"BJ Maron","year":"1986","unstructured":"Maron BJ, Wolfson JK, Epstein SE, Roberts WC (1986) Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 8(3):545\u2013557","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"10535_CR32","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","volume":"115","author":"RL Anderson","year":"2018","unstructured":"Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H et al (2018) Deciphering the super relaxed state of human \u03b2-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. Proc Natl Acad Sci USA 115(35):E8143\u2013E8152","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10535_CR33","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P et al (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41(10):1776\u20131782","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10535_CR34","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1161\/circ.104.25.e165","volume":"104","author":"H Ashrafian","year":"2001","unstructured":"Ashrafian H, Watkins H (2001) Myocardial dysfunction in hypertrophic cardiomyopathy. Circulation 104(25):E165","journal-title":"Circulation"},{"issue":"16","key":"10535_CR35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I et al (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122(16):1562\u20131569","journal-title":"Circulation"},{"issue":"11","key":"10535_CR36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrcardio.2016.98","volume":"13","author":"JOM Ormerod","year":"2016","unstructured":"Ormerod JOM, Frenneaux MP, Sherrid MV (2016) Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy. Nat Rev Cardiol 13(11):677\u2013687","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"10535_CR37","doi-asserted-by":"crossref","first-page":"8128","DOI":"10.3390\/ijms25158128","volume":"25","author":"G Canciello","year":"2024","unstructured":"Canciello G, Lombardi R, Borrelli F, Ordine L, Chen SN, Santoro C et al (2024) Echocardiographic strain abnormalities precede left ventricular hypertrophy development in hypertrophic cardiomyopathy mutation carriers. Int J Mol Sci 25(15):8128","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10535_CR38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.echo.2022.03.012","volume":"35","author":"SF Nagueh","year":"2022","unstructured":"Nagueh SF, Phelan D, Abraham T, Armour A, Desai MY, Dragulescu A et al (2022) Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 35(6):533\u2013569","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"10535_CR39","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S0735-1097(00)00816-0","volume":"36","author":"S Sharma","year":"2000","unstructured":"Sharma S, Elliott PM, Whyte G, Mahon N, Virdee MS, Mist B et al (2000) Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 36(3):864\u2013870","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10535_CR40","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.nuclcard.2007.08.003","volume":"14","author":"Q Ciampi","year":"2007","unstructured":"Ciampi Q, Betocchi S, Losi MA, Ferro A, Cuocolo A, Lombardi R et al (2007) Abnormal blood-pressure response to exercise and oxygen consumption in patients with hypertrophic cardiomyopathy. J Nucl Cardiol 14(6):869\u2013875","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"10535_CR41","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248","volume":"8","author":"CJ Coats","year":"2015","unstructured":"Coats CJ, Rantell K, Bartnik A, Patel A, Mist B, McKenna WJ et al (2015) Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. Circ Heart Fail 8(6):1022\u20131031","journal-title":"Circ Heart Fail"},{"issue":"11","key":"10535_CR42","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/jcm10112312","volume":"10","author":"A Bayonas-Ruiz","year":"2021","unstructured":"Bayonas-Ruiz A, Mu\u00f1oz-Franco FM, Ferrer V, P\u00e9rez-Caballero C, Sabater-Molina M, Tom\u00e9-Esteban MT et al (2021) Cardiopulmonary exercise test in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. J Clin Med 10(11):2312","journal-title":"J Clin Med"},{"issue":"2","key":"10535_CR43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/clc.4960260206","volume":"26","author":"M Nagata","year":"2003","unstructured":"Nagata M, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Taki J et al (2003) Hemodynamic changes and prognosis in patients with hypertrophic cardiomyopathy and abnormal blood pressure responses during exercise. Clin Cardiol 26(2):71\u201376","journal-title":"Clin Cardiol"},{"issue":"12","key":"10535_CR44","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.01.023","volume":"67","author":"MS Maron","year":"2016","unstructured":"Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B et al (2016) Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 67(12):1399\u20131409","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10535_CR45","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1161\/CIRCHEARTFAILURE.114.001435","volume":"7","author":"EJ Rowin","year":"2014","unstructured":"Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM et al (2014) Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail 7(6):967\u2013975","journal-title":"Circ Heart Fail"},{"issue":"17","key":"10535_CR46","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/eurheartj\/ehq136","volume":"31","author":"P Melacini","year":"2010","unstructured":"Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B et al (2010) Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 31(17):2111\u20132123","journal-title":"Eur Heart J"},{"issue":"12","key":"10535_CR47","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.amjcard.2009.07.057","volume":"104","author":"E Biagini","year":"2009","unstructured":"Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F et al (2009) Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy. Am J Cardiol 104(12):1727\u20131731","journal-title":"Am J Cardiol"},{"issue":"25","key":"10535_CR48","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.jacc.2007.02.061","volume":"49","author":"T Kubo","year":"2007","unstructured":"Kubo T, Gimeno JR, Bahl A, Steffensen U, Steffensen M, Osman E et al (2007) Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49(25):2419\u20132426","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10535_CR49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.echo.2020.05.010","volume":"33","author":"YL Hiemstra","year":"2020","unstructured":"Hiemstra YL, van der Bijl P, el Mahdiui M, Bax JJ, Delgado V, Marsan NA (2020) Myocardial work in nonobstructive hypertrophic cardiomyopathy: implications for outcome. J Am Soc Echocardiogr 33(10):1201\u20131208","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"10535_CR50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/echo.14210","volume":"36","author":"E Galli","year":"2019","unstructured":"Galli E, Vitel E, Schnell F, Le Rolle V, Hubert A, Lederlin M et al (2019) Myocardial constructive work is impaired in hypertrophic cardiomyopathy and predicts left ventricular fibrosis. Echocardiography 36(1):74\u201382","journal-title":"Echocardiography"},{"issue":"6","key":"10535_CR51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2015.06.018","volume":"116","author":"I Pozios","year":"2015","unstructured":"Pozios I, Corona-Villalobos C, Sorensen LL, Bravo PE, Canepa M, Pisanello C et al (2015) Comparison of outcomes in patients with nonobstructive, labile-obstructive, and chronically obstructive hypertrophic cardiomyopathy. Am J Cardiol 116(6):938\u2013944","journal-title":"Am J Cardiol"},{"issue":"5","key":"10535_CR52","doi-asserted-by":"crossref","first-page":"e006657","DOI":"10.1161\/JAHA.117.006657","volume":"7","author":"DY Lu","year":"2018","unstructured":"Lu DY, Pozios I, Haileselassie B, Ventoulis I, Liu H, Sorensen LL et al (2018) Clinical outcomes in patients with nonobstructive, labile, and obstructive hypertrophic cardiomyopathy. J Am Heart Assoc 7(5):e006657","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10535_CR53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjmed.2016.09.015","volume":"130","author":"BJ Maron","year":"2017","unstructured":"Maron BJ, Rowin EJ, Maron MS, Braunwald E (2017) Nonobstructive hypertrophic cardiomyopathy out of the shadows: known from the beginning but largely ignored \u2026 until now. Am J Med 130(2):119\u2013123","journal-title":"Am J Med"},{"issue":"18","key":"10535_CR54","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2015.02.061","volume":"65","author":"BJ Maron","year":"2015","unstructured":"Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM et al (2015) Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies. J Am Coll Cardiol 65(18):1915\u20131928","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10535_CR55","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","volume":"126","author":"P Sorajja","year":"2012","unstructured":"Sorajja P, Ommen SR, Holmes DR, Dearani JA, Rihal CS, Gersh BJ et al (2012) Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 126(20):2374\u20132380","journal-title":"Circulation"},{"key":"10535_CR56","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijcard.2017.06.071","volume":"243","author":"F Pelliccia","year":"2017","unstructured":"Pelliccia F, Pasceri V, Limongelli G, Autore C, Basso C, Corrado D et al (2017) Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 243:379\u2013384","journal-title":"Int J Cardiol"},{"issue":"4","key":"10535_CR57","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0735-1097(01)01778-8","volume":"39","author":"MJ Eriksson","year":"2002","unstructured":"Eriksson MJ, Sonnenberg B, Woo A, Rakowski P, Parker TG, Wigle ED et al (2002) Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol 39(4):638\u2013645","journal-title":"J Am Coll Cardiol"},{"key":"10535_CR58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ijcard.2016.07.154","volume":"222","author":"MF Jan","year":"2016","unstructured":"Jan MF, Todaro MC, Oreto L, Tajik AJ (2016) Apical hypertrophic cardiomyopathy: present status. Int J Cardiol 222:745\u2013759","journal-title":"Int J Cardiol"},{"issue":"5","key":"10535_CR59","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jcmg.2020.09.037","volume":"14","author":"M Habib","year":"2021","unstructured":"Habib M, Adler A, Fardfini K, Hoss S, Hanneman K, Rowin EJ et al (2021) Progression of myocardial fibrosis in hypertrophic cardiomyopathy: a cardiac magnetic resonance study. JACC Cardiovasc Imaging 14(5):947\u2013958","journal-title":"JACC Cardiovasc Imaging"},{"key":"10535_CR60","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijcard.2023.04.006","volume":"381","author":"M Lee","year":"2023","unstructured":"Lee M, Shechter A, Han D, Nguyen LC, Kim MS, Berman DS et al (2023) Left ventricular morphologic progression in apical hypertrophic cardiomyopathy. Int J Cardiol 381:62\u201369","journal-title":"Int J Cardiol"},{"issue":"23","key":"10535_CR61","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jacc.2011.02.033","volume":"57","author":"Y Minami","year":"2011","unstructured":"Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S et al (2011) Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 57(23):2346\u20132355","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10535_CR62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jjcc.2014.03.003","volume":"64","author":"Y Minami","year":"2014","unstructured":"Minami Y, Haruki S, Hagiwara N (2014) Phenotypic overlap in hypertrophic cardiomyopathy: apical hypertrophy, midventricular obstruction, and apical aneurysm. J Cardiol 64(6):463\u2013469","journal-title":"J Cardiol"},{"issue":"11","key":"10535_CR63","doi-asserted-by":"crossref","first-page":"e015555","DOI":"10.1161\/CIRCIMAGING.123.015555","volume":"16","author":"M Habib","year":"2023","unstructured":"Habib M, Hoss S, Adler A, Katz O, Halloun Habib H, Fardfini K et al (2023) Apical aneurysm development in hypertrophic cardiomyopathy. Circulation. Cardiovasc Imaging 16(11):e015555","journal-title":"Cardiovasc Imaging"},{"issue":"8","key":"10535_CR64","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.echo.2022.04.010","volume":"35","author":"M Strachinaru","year":"2022","unstructured":"Strachinaru M, Huurman R, Bowen DJ, Schinkel AFL, Hirsch A, Michels M (2022) Relation between early diastolic mid-ventricular flow and elastic forces indicating aneurysm formation in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 35(8):846\u2013856e2","journal-title":"J Am Soc Echocardiogr"},{"issue":"25","key":"10535_CR65","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","volume":"76","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P et al (2020) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 76(25):e159\u2013e240","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10535_CR66","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0002-9149(94)90151-1","volume":"73","author":"MA Losi","year":"1994","unstructured":"Losi MA, Betocchi S, Grimaldi M, Spampinato N, Chiariello M (1994) Heterogeneity of left ventricular filling dynamics in hypertrophic cardiomyopathy. Am J Cardiol 73(13):987\u2013990","journal-title":"Am J Cardiol"},{"issue":"13","key":"10535_CR67","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1001\/jama.2017.2503","volume":"317","author":"S Saberi","year":"2017","unstructured":"Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A et al (2017) Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA 317(13):1349\u20131357","journal-title":"JAMA"},{"issue":"9","key":"10535_CR68","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","volume":"18","author":"E Ammirati","year":"2016","unstructured":"Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I (2016) Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail 18(9):1106\u20131118","journal-title":"Eur J Heart Fail"},{"issue":"10253","key":"10535_CR69","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396(10253):759\u2013769","journal-title":"Lancet"},{"issue":"20","key":"10535_CR70","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N et al (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med 390(20):1849\u20131861","journal-title":"N Engl J Med"},{"issue":"10","key":"10535_CR71","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s40265-022-01739-7","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ (2022) Mavacamten: first approval. Drugs 82(10):1127\u20131135","journal-title":"Drugs"},{"issue":"6273","key":"10535_CR72","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621","journal-title":"Science"},{"issue":"8","key":"10535_CR73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","volume":"3","author":"JJ Hartman","year":"2024","unstructured":"Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S et al (2024) Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res 3(8):1003\u20131016","journal-title":"Nat Cardiovasc Res"},{"issue":"25","key":"10535_CR74","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1161\/CIRCULATIONAHA.121.053527","volume":"143","author":"H Watkins","year":"2021","unstructured":"Watkins H (2021) Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation 143(25):2415\u20132417","journal-title":"Circulation"},{"issue":"21","key":"10535_CR75","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"CY Ho","year":"2020","unstructured":"Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM et al (2020) Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 75(21):2649\u20132660","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10535_CR76","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cardfail.2024.02.020","volume":"30","author":"A Masri","year":"2024","unstructured":"Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM et al (2024) Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM Trial, Cohort 4. J Card Fail 30(11):1439\u20131448","journal-title":"J Card Fail"},{"key":"10535_CR77","first-page":"101467","volume":"53","author":"I Ullah","year":"2024","unstructured":"Ullah I, Tayyaba Rehan S, Khan Z, Hasan Shuja S, Hamza Shuja M, Irfan M et al (2024) Efficacy and safety of mavacamten for symptomatic hypertrophic cardiomyopathy - an updated meta-analysis of randomized controlled trials. Int J Cardiol Heart Vasc 53:101467","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"2","key":"10535_CR78","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Nissen SE, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD et al (2025) Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy: design, rationale, and baseline characteristics of ODYSSEY-HCM. JACC Heart Fail 13(2):358\u2013370","journal-title":"JACC Heart Fail"},{"issue":"2","key":"10535_CR79","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s12265-023-10441-2","volume":"17","author":"F Borrelli","year":"2024","unstructured":"Borrelli F, Lombardi R, Canciello G, Frisso G, Todde G, Esposito G et al (2024) Mechano-energetic efficiency in patients with hypertrophic cardiomyopathy with and without sarcomeric mutations. J Cardiovasc Transl Res 17(2):458\u2013466","journal-title":"J Cardiovasc Transl Res"},{"issue":"21","key":"10535_CR80","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","volume":"83","author":"MS Maron","year":"2024","unstructured":"Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ et al (2024) Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 83(21):2037\u20132048","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10535_CR81","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.jacc.2020.09.542","volume":"76","author":"JA Spertus","year":"2020","unstructured":"Spertus JA, Jones PG, Sandhu AT, Arnold SV (2020) Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 76(20):2379\u20132390","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10535_CR82","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2024.04.006","volume":"83","author":"AV Ambardekar","year":"2024","unstructured":"Ambardekar AV, Kopecky BJ, Raymer DS (2024) Finding an unobstructed view toward the treatment of nonobstructive hypertrophic cardiomyopathy: lifting the hunger fog. J Am Coll Cardiol 83(21):2049\u20132051","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10535_CR83","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1093\/eurheartj\/ehad518","volume":"44","author":"A Weissler-Snir","year":"2023","unstructured":"Weissler-Snir A, Rakowski H, Meyer M (2023) Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction? Eur Heart J 44(37):3655\u20133657","journal-title":"Eur Heart J"},{"issue":"6","key":"10535_CR84","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/ejhf.3291","volume":"26","author":"L Velicki","year":"2024","unstructured":"Velicki L, Popovic D, Okwose NC, Preveden A, Tesic M, Tafelmeier M et al (2024) Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM). Eur J Heart Fail 26(6):1361\u20131368","journal-title":"Eur J Heart Fail"},{"key":"10535_CR85","unstructured":"National Institute of Cardiology, Warsaw, Poland. The use of empagliflozin in patients with hypertrophic cardiomyopathy [Internet]. clinicaltrials.gov; 2023 Oct [cited 2025 Jan 8]. Report No.: NCT05182658. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05182658"},{"issue":"10","key":"10535_CR86","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","volume":"27","author":"CY Ho","year":"2021","unstructured":"Ho CY, Day SM, Axelsson A, Russell MW, Zahka K, Lever HM et al (2021) Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 27(10):1818\u20131824","journal-title":"Nat Med"},{"issue":"1","key":"10535_CR87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacep.2018.08.018","volume":"5","author":"EJ Rowin","year":"2019","unstructured":"Rowin EJ, Mohanty S, Madias C, Maron BJ, Maron MS (2019) Benefit of cardiac resynchronization therapy in end-stage nonobstructive hypertrophic cardiomyopathy. JACC Clin Electrophysiol 5(1):131\u2013133","journal-title":"JACC Clin Electrophysiol"},{"issue":"20","key":"10535_CR88","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.117.030593","volume":"136","author":"A Nguyen","year":"2017","unstructured":"Nguyen A, Schaff HV, Nishimura RA, Dearani JA, Ommen SR (2017) Early outcomes of repair of left ventricular apical aneurysms in patients with hypertrophic cardiomyopathy. Circulation 136(20):1979\u20131981","journal-title":"Circulation"},{"issue":"23","key":"10535_CR89","first-page":"e471","volume":"150","author":"Y Kim","year":"2024","unstructured":"Kim Y, Landstrom AP, Shah SH, Wu JC, Seidman CE, American Heart Association (2024) Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association. Circulation 150(23):e471\u2013e480","journal-title":"Circulation"},{"issue":"6","key":"10535_CR90","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16(6):1073\u20131080","journal-title":"Mol Ther"},{"key":"10535_CR91","doi-asserted-by":"crossref","unstructured":"Tenaya Therapeutics. First-in-human, open-label, safety, tolerability, dose-finding, pharmacodynamic and cardiac transgene expression study of TN-201, a recombinant adeno-associated virus serotype 9 (AAV9) containing myosin binding protein C transgene, in adults with MYBPC3 mutation-associated hypertrophic cardiomyopathy (HCM) [Internet]. clinicaltrials gov; 2024 Nov [cited 2024 Dec 30]. Report No.: NCT05836259. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05836259","DOI":"10.1016\/j.cardfail.2023.11.010"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10535-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10535-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10535-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:04:33Z","timestamp":1763150673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10535-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,14]]},"references-count":91,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10535"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10535-w","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,14]]},"assertion":[{"value":"3 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}